- Home
- ELEV vs RAVE Comparison
ELEV vs RAVE Comparison
Compare ELEV & RAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- RAVE
- Stock Information
- Founded
- ELEV 2019
- RAVE 1958
- Country
- ELEV United States
- RAVE United States
- Employees
- ELEV N/A
- RAVE N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- RAVE Restaurants
- Sector
- ELEV Health Care
- RAVE Consumer Discretionary
- Exchange
- ELEV Nasdaq
- RAVE Nasdaq
- Market Cap
- ELEV 22.0M
- RAVE N/A
- IPO Year
- ELEV 2021
- RAVE N/A
- Fundamental
- Price
- ELEV $0.36
- RAVE $2.62
- Analyst Decision
- ELEV Buy
- RAVE
- Analyst Count
- ELEV 6
- RAVE 0
- Target Price
- ELEV $2.94
- RAVE N/A
- AVG Volume (30 Days)
- ELEV 996.3K
- RAVE 16.7K
- Earning Date
- ELEV 05-16-2025
- RAVE 05-08-2025
- Dividend Yield
- ELEV N/A
- RAVE N/A
- EPS Growth
- ELEV N/A
- RAVE 25.22
- EPS
- ELEV N/A
- RAVE 0.19
- Revenue
- ELEV N/A
- RAVE $12,240,000.00
- Revenue This Year
- ELEV N/A
- RAVE N/A
- Revenue Next Year
- ELEV N/A
- RAVE N/A
- P/E Ratio
- ELEV N/A
- RAVE $13.84
- Revenue Growth
- ELEV N/A
- RAVE 3.35
- 52 Week Low
- ELEV $0.22
- RAVE $1.70
- 52 Week High
- ELEV $4.33
- RAVE $3.36
- Technical
- Relative Strength Index (RSI)
- ELEV 52.69
- RAVE 60.52
- Support Level
- ELEV $0.34
- RAVE $2.30
- Resistance Level
- ELEV $0.36
- RAVE $2.50
- Average True Range (ATR)
- ELEV 0.03
- RAVE 0.12
- MACD
- ELEV 0.00
- RAVE 0.04
- Stochastic Oscillator
- ELEV 50.00
- RAVE 78.33
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.